Sirius Therapeutics Appoints Patrick Yue, MD, as Chief Medical Officer

Shanghai and San Diego, CA – July 8, 2024 - Sirius Therapeutics announces the appointment of Patrick Yue, MD, as Chief Medical Officer. Dr. Yue has extensive leadership experience in clinical development including the anti-coagulant therapeutic area, most recently at Centessa Pharmaceuticals.

“Patrick is a seasoned pharmaceutical executive who brings an outstanding track record in leading successful clinical development programs,” said Qunsheng Ji, MD, PhD, Sirius Therapeutics’ CEO. “He has played central roles in the development and marketing approval of multiple products in the U.S, and globally, including ANDEXXA® (coagulation factor Xa [recombinant], inactivated-zhzo) and OXBRYTA® (voxelotor). He joins Sirius at a right time, when our first two siRNA programs are advancing towards mid-stage of clinical development, with additional compounds moving to clinic.”

At Centessa，Dr. Yue oversaw the clinical development of two investigational products: SerpinPC, an activated Protein C inhibitor in Phase 2b/3 studies for the treatment of hemophilia, and ORX-750, an orexin agonist in development for the treatment of narcolepsy. He also served as a member of the executive leadership team. Prior to Centessa, Dr. Yue served at Global Blood Therapeutics, as Vice President, and Head of Clinical Science. During his tenure, he oversaw the clinical development of four products, including the marketing approval in the EU of voxelotor (OXBRYTA®) for the treatment of sickle cell disease and a label expansion for pediatric use in the U.S. Previously, he led the clinical development of ANDEXXA through its approval in the US and the EU at Portola Pharmaceuticals.

Prior to joining industry, Dr. Yue completed his medical internship and residency at Beth Israel Deaconess Medical Center and received specialty training in cardiovascular medicine at Stanford University School of Medicine. Dr. Yue holds a BS in biology and chemistry from the California Institute of Technology and an MD from Washington University School of Medicine.

About Sirius Therapeutics

Sirius is an innovative, clinical stage biotech company developing next generation siRNA therapies for global markets. We are dedicated to discovering and developing new treatment options for cardiovascular disease patients. Our most advanced programs are SRSD107 for the treatment of thromboembolic disorders, and SRSD101 for the treatment of dyslipidemia. Founded in 2021 by a world-class leadership team and investors, Sirius has established an innovative discovery center in the US and a translational center in China. Sirius has raised nearly US$100 million funding to date from OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital and the leadership team. Learn more at www.siriusrna.com.